세계의 심원성 쇼크 시장 : 치료 유형별, 최종사용자별, 지역별, 규모, 동향, COVID-19의 영향 분석, 예측(-2030년)

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's needs. It is most commonly caused by a severe heart attack (myocardial infarction) but can also result from other heart conditions such as heart failure, arrhythmias, myocarditis, or valve disorders. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to reach US$5.20 billion by 2030.

The global cardiogenic shock market is poised for significant growth, driven by the rising prevalence of cardiovascular diseases (CVDs), increasing adoption of advanced mechanical circulatory support devices, and growing awareness regarding early diagnosis and treatment. The surge in aging populations, who are more prone to heart-related conditions, further accelerates market expansion. Technological advancements in treatment options, such as percutaneous ventricular assist devices (pVADs) and extracorporeal membrane oxygenation (ECMO), are improving patient survival rates and driving demand. Additionally, increasing healthcare expenditures, favorable reimbursement policies, and the rising number of clinical trials for novel therapies contribute to market growth. The integration of artificial intelligence (AI) in diagnostic tools and real-time monitoring systems is also enhancing treatment outcomes, further boosting the global cardiogenic shock market. The global cardiogenic shock market value is projected to grow at a CAGR of 6.47%, during the forecast period of 2025-2030.

Market Segmentation Analysis:

By Treatment Type: According to the report, the global cardiogenic shock market is bifurcated into three segments based on the treatment type: drugs, mechanical circulatory support (MCS) devices and others. Drugs segment acquired majority of share in the market in 2024 due to the widespread use of vasopressors, inotropes, and anticoagulants as first-line treatments to stabilize patients and restore hemodynamic function. These medications are readily available, cost-effective, and crucial for immediate management, contributing to their significant market share. However, the mechanical circulatory support (MCS) devices segment is expected to grow the fastest due to the increasing adoption of advanced life-saving technologies such as intra-aortic balloon pumps (IABPs), percutaneous ventricular assist devices (pVADs), and extracorporeal membrane oxygenation (ECMO). These devices offer superior efficacy in maintaining cardiac output and reducing mortality rates in severe cardiogenic shock cases, especially when drug therapy alone is insufficient. Additionally, continuous technological advancements, increasing clinical evidence supporting their benefits, and growing healthcare investments in critical care infrastructure are fueling the rapid expansion of the MCS devices segment.

By End-user: According to the report, the global cardiogenic shock market is bifurcated into four types of end-users: hospitals & clinics, specialty cardiac centers, ambulatory surgical centers and others. Hospitals segment acquired the majority share in the global cardiogenic shock market in 2024 and is also the fastest-growing segment due to the high patient influx, availability of advanced treatment options, and presence of specialized cardiac care units. Hospitals are the primary centers for managing cardiogenic shock, offering 24/7 emergency care, intensive monitoring, and access to life-saving interventions such as mechanical circulatory support (MCS) devices, extracorporeal membrane oxygenation (ECMO), and catheter-based procedures. The increasing number of hospital admissions due to the rising prevalence of cardiovascular diseases (CVDs) and the growing elderly population further drive this segment's growth. Additionally, hospitals benefit from higher healthcare investments, government funding, and favorable reimbursement policies. The expansion of multi-specialty hospitals and the rising focus on improving critical care infrastructure further contribute to the segment's rapid growth in the global cardiogenic shock market.

By Region: The report provides insight into the cardiogenic shock market based on the geographical operations, namely, North America, Europe, Asia Pacific and rest of the world. North America cardiogenic shock market enjoyed the highest market share in 2024 due to its well-established healthcare infrastructure, high prevalence of cardiovascular diseases (CVDs), and widespread adoption of advanced treatment options. The region also benefits from strong government initiatives, favorable reimbursement policies, and extensive research and development activities aimed at improving cardiogenic shock management. However, the Asia Pacific market is expected to grow the fastest during the forecast period due to the rising incidence of cardiovascular diseases, increasing healthcare expenditure, and improving access to advanced medical treatments. Rapid urbanization, a growing aging population, and lifestyle changes leading to higher risk factors such as diabetes and hypertension further contribute to market expansion. Additionally, the region is witnessing significant investments in healthcare infrastructure, an increasing number of specialized cardiac centers, and greater awareness about early diagnosis and treatment of cardiogenic shock, driving its rapid growth.

Global Cardiogenic Shock Market Dynamics:

Growth Drivers: One of the most important factors driving the growth of global cardiogenic shock market is increase in the global geriatric population. The increasing global geriatric population is a key driver of growth in the cardiogenic shock market, as aging is a major risk factor for cardiovascular diseases (CVDs), including heart attacks, heart failure, and cardiogenic shock. Older adults are more likely to develop comorbidities such as hypertension, diabetes, and atherosclerosis, which contribute to cardiac complications and increase the likelihood of cardiogenic shock. With advancements in healthcare extending life expectancy, the number of elderly individuals requiring critical cardiac care is rising, driving demand for both pharmaceutical and mechanical interventions. Other factors driving the growth of global cardiogenic shock market include increasing incidence of heart disease, growing healthcare expenditure, growing prevalence of sedentary lifestyle, rising awareness and early diagnosis etc.

Challenges: One significant challenge faced by the global cardiogenic shock market is high cost of advanced therapies and devices. The high cost of advanced therapies and mechanical circulatory support (MCS) devices poses a significant challenge to the growth of the global cardiogenic shock market. Treatments such as extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices (pVADs), and intra-aortic balloon pumps (IABPs) are highly effective but come with substantial costs, making them less accessible, especially in low- and middle-income countries. The expenses associated with these technologies include not only the initial procurement but also ongoing maintenance, specialized healthcare personnel, and intensive post-procedure care, further increasing the financial burden on healthcare systems and patients. Another challenge might include shortage of skilled staff etc.

Trends: The adoption of minimally invasive techniques is a significant trend in the global cardiogenic shock market due to their ability to improve patient outcomes while reducing recovery time, complications, and hospital stays. Procedures such as percutaneous coronary intervention (PCI), percutaneous ventricular assist devices (pVADs), and catheter-based extracorporeal membrane oxygenation (ECMO) offer effective support for patients in cardiogenic shock with less trauma compared to traditional open-heart surgeries. These techniques allow for quicker stabilization of patients, leading to lower mortality rates and improved long-term prognosis. Additionally, advancements in interventional cardiology, along with the increasing preference for minimally invasive procedures among physicians and patients, are driving their widespread adoption. The growing availability of specialized catheter-based interventions and the expansion of hybrid operating rooms in hospitals further support this trend. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as rise in adoption of artificial intelligence, technological advancements, development of novel pharmacological therapies, rise in research and development activities, rising demand for point-of-care testing etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic initially disrupted the global cardiogenic shock market due to delays in non-emergency cardiac procedures, strained healthcare resources, and supply chain challenges. However, post-COVID-19, the market rebounded with increased investments in critical care infrastructure, growing awareness of cardiovascular complications linked to COVID-19, and accelerated adoption of advanced treatment modalities.

Competitive Landscape and Recent Developments:

The global cardiogenic shock market is characterized by a moderately consolidated landscape, with a few dominant players holding significant market shares, while smaller companies also contribute to the market dynamics. Key players of global cardiogenic shock market are:

Abbott

Medtronic plc

Boston Scientific Corporation

AstraZeneca Plc

Roche Holdings AG

Bayer AG

Getinge

Johnson & Johnson (Abiomed)

Viatris Inc.

Terumo Corporation

Endo International plc (Par Pharmaceutical)

Windtree Therapeutics Inc.

ZOLL Medical Corporation

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their products to emerging markets and more, to maintain a competitive edge in this market. For instance, In October 2024, Abbott announced the initiation of the TEAM-HF clinical trial, a groundbreaking study designed to improve outcomes for patients with worsening heart failure and In January 2024, Windtree Therapeutics announced a licensed agreement with Lee's Pharmaceuticals to develop and commercialize a positive inotropic agent called Istraoxime to improve systolic and diastolic cardiac function.

Table of Contents

1. Executive Summary

2. Introduction

• 2.1 Cardiogenic Shock: An Overview
  • 2.1.1 Introduction to Cardiogenic Shock
  • 2.1.2 Ways to Reduce Cardiogenic Shock Risk
• 2.2 Cardiogenic Shock Segmentation: An Overview
  • 2.2.1 Cardiogenic Shock Segmentation

3. Global Market Analysis

• 3.1 Global Cardiogenic Shock Market: An Analysis
  • 3.1.1 Global Cardiogenic Shock Market: An Overview
  • 3.1.2 Global Cardiogenic Shock Market by Value
  • 3.1.3 Global Cardiogenic Shock Market by Treatment Type
  • 3.1.4 Global Cardiogenic Shock Market by End-user
  • 3.1.5 Global Cardiogenic Shock Market by Region
• 3.2 Global Cardiogenic Shock Market: Treatment Type Analysis
  • 3.2.1 Global Cardiogenic Shock Market by Treatment Type: An Overview
  • 3.2.2 Global Drugs Cardiogenic Shock Market by Value
  • 3.2.3 Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value
  • 3.2.4 Global Other Cardiogenic Shock Market by Value
• 3.3 Global Cardiogenic Shock Market: End-user Analysis
  • 3.3.1 Global Cardiogenic Shock Market by End-user: An Overview
  • 3.3.2 Global Hospitals & Clinics Cardiogenic Shock Market by Value
  • 3.3.3 Global Specialty Cardiac Centers Cardiogenic Shock Market by Value
  • 3.3.4 Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value
  • 3.3.5 Global Others Cardiogenic Shock Market by Value

4. Regional Market Analysis

• 4.1 North America Cardiogenic Shock Market: An Analysis
  • 4.1.1 North America Cardiogenic Shock Market: An Overview
  • 4.1.2 North America Cardiogenic Shock Market by Value
  • 4.1.3 North America Cardiogenic Shock Market by Region
  • 4.1.4 The US Cardiogenic Shock Market by Value
  • 4.1.5 Canada Cardiogenic Shock Market by Value
  • 4.1.6 Mexico Cardiogenic Shock Market by Value
• 4.2 Europe Cardiogenic Shock Market: An Analysis
  • 4.2.1 Europe Cardiogenic Shock Market: An Overview
  • 4.2.2 Europe Cardiogenic Shock Market by Value
  • 4.2.3 Europe Cardiogenic Shock Market by Region
  • 4.2.4 Germany Cardiogenic Shock Market by Value
  • 4.2.5 United Kingdom Cardiogenic Shock Market by Value
  • 4.2.6 France Cardiogenic Shock Market by Value
  • 4.2.7 Italy Cardiogenic Shock Market by Value
  • 4.2.8 Spain Cardiogenic Shock Market by Value
  • 4.2.9 Rest of Europe Cardiogenic Shock Market by Value
• 4.3 Asia Pacific Cardiogenic Shock Market: An Analysis
  • 4.3.1 Asia Pacific Cardiogenic Shock Market: An Overview
  • 4.3.2 Asia Pacific Cardiogenic Shock Market by Value
  • 4.3.3 Asia Pacific Cardiogenic Shock Market by Region
  • 4.3.4 China Cardiogenic Shock Market by Value
  • 4.3.5 Japan Cardiogenic Shock Market by Value
  • 4.3.6 India Cardiogenic Shock Market by Value
  • 4.3.7 South Korea Cardiogenic Shock Market by Value
  • 4.3.8 Rest of Asia Pacific Cardiogenic Shock Market by Value
• 4.4 Latin America Cardiogenic Shock Market: An Analysis
  • 4.4.1 Latin America Cardiogenic Shock Market: An Overview
  • 4.4.2 Latin America Cardiogenic Shock Market by Value
• 4.5 Middle East & Africa Cardiogenic Shock Market: An Analysis
  • 4.5.1 Middle East & Africa Cardiogenic Shock Market: An Overview
  • 4.5.2 Middle East & Africa Cardiogenic Shock Market by Value

5. Impact of COVID-19

• 5.1 Impact of COVID-19 on Global Cardiogenic Shock Market
• 5.2 Post COVID-19 Impact on Global Cardiogenic Shock Market

6. Market Dynamics

• 6.1 Growth Drivers
  • 6.1.1 Increase in the Global Geriatric Population
  • 6.1.2 Increasing Incidence of Heart Disease
  • 6.1.3 Growing Healthcare Expenditure
  • 6.1.4 Growing Prevalence of Sedentary Lifestyle
  • 6.1.5 Rising Awareness and Early Diagnosis
• 6.2 Challenges
  • 6.2.1 High Cost of Advanced Therapies and Devices
  • 6.2.2 Shortage of Skilled Healthcare Professionals
• 6.3 Market Trends
  • 6.3.1 Rise in Adoption of Artificial Intelligence
  • 6.3.2 Technological Advancements in Mechanical Circulatory Support (MCS) Devices
  • 6.3.3 Development of Novel Pharmacological Therapies
  • 6.3.4 Rise in Research and Development Activities
  • 6.3.5 Adoption of Minimally Invasive Techniques
  • 6.3.6 Rising Demand for Point-of-Care (POC) Testing

7. Competitive Landscape

• 7.1 Global Cardiogenic Shock Market Players: Recent Developments

8. Company Profiles

• 8.1 Abbott
  • 8.1.1 Business Overview
  • 8.1.2 Operating Segments
  • 8.1.3 Business Strategy
• 8.2 Medtronic plc
  • 8.2.1 Business Overview
  • 8.2.2 Operating Segments
  • 8.2.3 Business Strategy
• 8.3 Boston Scientific Corporation
  • 8.3.1 Business Overview
  • 8.3.2 Operating Segments
  • 8.3.3 Business Strategy
• 8.4 AstraZeneca Plc
  • 8.4.1 Business Overview
  • 8.4.2 Business Strategies
• 8.5 Roche Holdings AG
  • 8.5.1 Business Overview
  • 8.5.2 Operating Segments
  • 8.5.3 Business Strategy
• 8.6 Bayer AG
  • 8.6.1 Business Overview
  • 8.6.2 Operating Segments
  • 8.6.3 Business Strategy
• 8.7 Getinge
  • 8.7.1 Business Overview
  • 8.7.2 Operating Segments
  • 8.7.3 Business Strategy
• 8.8 Johnson & Johnson (Abiomed)
  • 8.8.1 Business Overview
  • 8.8.2 Business Segments
  • 8.8.3 Business Strategy
• 8.9 Viatris, Inc.
  • 8.9.1 Business Overview
  • 8.9.2 Operating Segments
  • 8.9.3 Business Strategy
• 8.10 Terumo Corporation
  • 8.10.1 Business Overview
  • 8.10.2 Operating Segments
  • 8.10.3 Business Strategy
• 8.11 Endo International plc (Par Pharmaceutical)
  • 8.11.1 Business Overview
  • 8.11.2 Operating Segments
  • 8.11.3 Business Strategy
• 8.12 Windtree Therapeutics, Inc.
  • 8.12.1 Business Overview
  • 8.12.2 Business Strategy
• 8.13 ZOLL Medical Corporation
  • 8.13.1 Business Overview
  • 8.13.2 Business Strategy